Neos Therapeutics licenses pipeline candidate for treatment of sialorrhea
Neos Therapeutics announced it has licensed NRX 101, a candidate for treatment of sialorrhea (excessive salivation or drooling) from NeuRx Pharmaceuticals. This candidate will now be known as NT0501 and is a new chemical entity and a selective muscarinic receptor antagonist. October 23, 2018